Long NM, Burns TA, Volpi Lagreca G, Alende M and Duckett SK
Objectives: The objectives of these studies are to evaluate: 1) uptake of a pulse dose of 13C16:1 cis-9 at varying levels into the blood and 2) glucose and insulin changes after pulse dose of 0 or 5 mg C16:1 cis-9/kg body weight (BW) under challenge conditions in obese lambs.
Methods: Two experiments were conducted to evaluate uptake of U-13C16:1 cis-9 into the blood and changes in glucose and insulin under challenges. In the first experiment, lambs (67.4 ± 1.4 kg BW, n=3) received jugular catheters and were used in a 3 x 3 Latin square. Treatments were 0, 2 or 5 mg/kg BW of U-13C16:1 cis-9 in 40% (wt/v) ethanol and blood samples were collected post infusion for glucose, fatty acid and insulin analyses. In the second experiment, lambs (86.7 ± 1.5 kg BW; n=4) received jugular catheters. Treatments were 0 or 5 mg/kg BW of C16:1 in 40% (wt/v) ethanol immediately followed by a glucose (0.25 g/kg) or insulin (0.02 mIU/kg) challenge.
Results: Both the 2 and 5 mg/kg BW dose of U-13C16:1 cis-9increased (P=0.003) C16:1 cis-9in serum compared to 0 mg/kg BW. The 5 mg/kg BW dose had a greater magnitude of increase for serum C16:1 and resulted in increased whole blood glucose levels for first 60 min and altered insulin levels for first 30 min. During the glucose tolerance test, C16:1bolus infusion increased (P=0.02) peak, overall, and area under the curve for plasma glucose levels. During the insulin challenge, C16:1-treated lambs had increased glucose levels (P=0.04) and peak, overall, and area under the curve plasma insulin (P=0.0001).
Conclusion: Palmitoleic acid infusion results in immediate uptake and clearance of serum palmitoleic acid, increases plasma glucose levels, and alters circulating insulin levels.
PDFShare this article
Journal of Metabolic Syndrome received 48 citations as per Google Scholar report
